Boldenone (Equipoise) Side Effects: Haematocrit, Thrombosis Risk & More (2026)

Boldenone (Equipoise) has a reputation among performance athletes for being a “mild” compound with manageable side effects. This reputation is partially earned — it is genuinely less androgenic than testosterone and produces less water retention than most mass-building injectables. However, it has one genuinely high-risk property that distinguishes it from most other anabolic steroids: its effect on red blood cell mass and blood viscosity. This guide provides a complete and accurate side effect assessment.

Side Effect Summary Table

Side Effect	Incidence	Severity	Management
Haematocrit elevation / polycythaemia	Universal	Potentially severe	Monitoring; phlebotomy if >54%
HPG axis suppression	Universal	Severe	PCT required
Oestrogenic effects (water retention)	Common at higher doses	Mild–Moderate	AI (Aromasin/Arimidex)
Androgenic effects (acne, hair loss)	Common	Moderate	Dose reduction
Cardiovascular (lipid disruption)	Universal	Moderate	Lipid monitoring; dietary management
Blood pressure elevation	Very common	Moderate	BP monitoring; lifestyle
Anxiety / mood effects	Uncommon	Mild	Dose reduction

The Primary Risk: Polycythaemia and Thrombosis

Boldenone's most clinically significant adverse effect is the elevation of haematocrit through EPO stimulation. When red blood cell mass rises above physiological norms, blood viscosity increases non-linearly. The consequences of hyperviscosity include:

• Deep vein thrombosis (DVT): Clot formation in deep veins, most commonly the legs
• Pulmonary embolism (PE): DVT clots that migrate to the pulmonary vasculature — potentially fatal
• Increased stroke risk: Higher viscosity blood is more likely to cause ischaemic cerebrovascular events
• Hypertension: Increased blood viscosity raises peripheral resistance and blood pressure

This is not a theoretical risk. Polycythaemia-related thrombotic events have been documented in AAS users, and boldenone is the anabolic compound most associated with this specific complication due to its pronounced EPO-stimulating activity.

Monitoring protocol: Haematocrit at baseline, week 4, week 8, and week 12. Target <52%. Action required at >54%: reduce dose; donate blood (therapeutic phlebotomy). See our harm reduction guide for full protocols.

HPG Axis Suppression

Like all anabolic steroids, boldenone suppresses LH and FSH, shutting down endogenous testosterone production. Because of its long half-life (14 days), the HPG axis may remain suppressed for 4–6 weeks after the last boldenone injection, significantly delaying PCT effectiveness if started too early. Wait 3 weeks after the last injection before initiating PCT. See our complete PCT guide for full protocols.

Oestrogenic Side Effects

Boldenone aromatises at approximately 50% the rate of testosterone. At doses commonly used in performance enhancement (400–600 mg/week), combined with a testosterone base, total oestrogen load can drive water retention and gynaecomastia risk. An AI is appropriate at these doses. The lower aromatisation rate means oestrogen-related side effects are easier to manage than with equivalent testosterone doses, but cannot be dismissed.

Androgenic Side Effects

With an androgenic rating of 50 (half that of testosterone), androgenic side effects are present but less pronounced than testosterone. Key concerns:

• Acne: Common on the back and shoulders. Improved hygiene and topical treatments typically adequate for mild cases.
• Hair loss: Risk is meaningful in genetically predisposed men. Finasteride is ineffective against boldenone's androgenic effect on hair follicles because it converts to dihydroboldenone (not DHT) via 5-alpha reductase.
• Virilisation in women: Women should not use boldenone. Even low doses carry significant virilisation risk due to the long ester and prolonged blood levels. For female anabolic steroid use, see our Anavar guide.

Cardiovascular Effects

Beyond haematocrit elevation and blood pressure increase, boldenone reduces HDL cholesterol and raises LDL, worsening the atherogenic lipid profile. The magnitude of these changes is generally less severe than with oral C-17aa steroids but comparable to injectable testosterone. See our cardiovascular and lipid monitoring guidance for appropriate protocols.

Anxiety and Psychological Effects

A subset of users report increased anxiety with boldenone, which has been attributed to its metabolite boldenone-1 having partial agonist activity at certain neurosteroid receptors. This is compound-specific and not reported with other injectables like Deca-Durabolin. If anxiety is significant, dose reduction or switching compounds is appropriate. See our boldenone complete guide for comparison with alternative compounds.

Frequently Asked Questions

Is Equipoise safer than Deca-Durabolin?

They have different risk profiles rather than one being unambiguously safer. Boldenone carries higher haematocrit/thrombosis risk. Deca-Durabolin carries progestogenic activity, prolactin elevation, and “Deca Dick” risk. Cardiovascular lipid effects are comparable. The choice depends on which risk profile is more manageable for the individual user. See our Deca-Durabolin side effects guide for comparison.

How long does boldenone stay in your system?

Boldenone undecylenate has an estimated detection window of up to 5 months in urine testing due to its long ester and lipophilic storage in adipose tissue. Athletes subject to drug testing should be aware that boldenone's detection window is among the longest of any common injectable steroid.